99
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib

ORCID Icon, ORCID Icon &
Pages 707-711 | Received 06 Nov 2023, Accepted 06 Mar 2024, Published online: 19 Mar 2024

References

  • Kroger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–1212. PMID: 22458952. doi:10.1111/j.1365-4632.2011.05377.x
  • Bergqvist C, Ezzedine K. Vitiligo: a focus on pathogenesis and its therapeutic implications. J Dermatol. 2021;48(3):252–270. PMID: 33404102. doi:10.1111/1346-8138.15743
  • Phan K, Phan S, Shumack S, Gupta M. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis. J DermatolTreat. 2022;33(1):173–177. PMID: 32096671. doi:10.1080/09546634.2020.1735615
  • Daniel BS, Wittal R. Vitiligo treatment update. Australas J Dermatol. 2015;56(2):85–92. PMID: 25495880. doi:10.1111/ajd.12256
  • Lee JH, Ju HJ, Seo JM, et al. Comorbidities in patients with vitiligo: a systematic review and meta-analysis. J Invest Dermatol. 2023;143(5):777–789.e6. PMID: 36574529. doi:10.1016/j.jid.2022.10.021
  • Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621–648. PMID: 32017656. doi:10.1146/annurev-immunol-100919-023531
  • Abdel Motaleb AA, Tawfik YM, El-Mokhtar MA, et al. Cutaneous jak expression in vitiligo. J Cutan Med Surg. 2021;25(2):157–162. PMID: 33174479. doi:10.1177/1203475420972340
  • Nada HR, El Sharkawy DA, Elmasry MF, et al. Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study. Arch Dermatol Res. 2018;310(1):39–46. PMID: 29127481. doi:10.1007/s00403-017-1792-6
  • Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. PMID: 31849996; PMCID: PMC6901833. doi:10.3389/fimmu.2019.02847
  • Joshipura D, Plotnikova N, Goldminz A. Importance of light in the treatment of vitiligo with JAK-inhibitors. J DermatolTreat. 2018;29(1):98–99. PMID: 28581823. doi:10.1080/09546634.2017.1339013
  • Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049. PMID: 25129481. doi:10.1038/nm.3645
  • Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054–1060 e1051. PMID: 28390737. doi:10.1016/j.jaad.2017.02.049
  • Relke N, Gooderham M. The use of janus kinase inhibitors in vitiligo: a review of the literature. J Cutan Med Surg. 2019;23(3):298–306. PMID: 30902022. doi:10.1177/1203475419833609
  • Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151(10):1110–1112. PMID: 26107994. doi:10.1001/jamadermatol.2015.1520
  • Hasni SA, Gupta S, Davis M. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. PMID: 34099646. doi:10.1038/s41467-021-23361-z